Biointron

A recent @Nature article looks at how AI is being applied to antibody discovery, particularly in designing binders with improved drug-like properties. The potential is clear: AI models may help reduce timelines and explore targets. nature.com/articles/s4158…

🌟 Thank You for Joining Us! 🌟 Biointron’s Lunch Networking with KACTUS in Cambridge last week was a success, thanks to all of you who attended! We were thrilled to host such an engaged audience and enjoyed connecting over both science and lunch. biointron.com/blog/2026-netw…

Read the latest on antibody developability trends from Biointron Monthly: 🔬 Developability is moving earlier in antibody discovery 📈 Multi-parameter profiling replacing single-assay evaluation 🤖 Machine learning expands predictive developability tools linkedin.com/pulse/antibody…

🌟 New article on the evolving role of early developability assessment in antibody discovery is in @FierceBiotech! 💡 fiercebiotech.com/sponsored/why-… #Biointron #Antibodies #Developability #DrugDevelopment #DrugDiscovery #Innovation #AntibodyProduction #Technolo fiercebiotech.com/sponsored/why-…

🎗️ New research highlights promising antibody strategies for targeting prostate cancer The team identified two lead candidates: • H92A5 – a PSMA-targeting antibody • EKA4 – an ACP3-specific antibody academic.oup.com/abt/article/8/…

💵 @EliLillyandCo pays $100M upfront for @CSLBehring IL-6 mAb clazakizumab, an anti-IL-6 monoclonal antibody. announcements.asx.com.au/asxpdf/2026021… #Biointron #Antibodies #Immunotherapy #PharmaNews #Healthcare #DrugDevelopment #DrugDiscovery #Oncology #Innovation #Networking

💵 Solstice Oncology will gain an exclusive worldwide license to Harbour BioMed’s porustobart, an anti-CTLA-4 antibody, in up to $1.2B deal. harbourbiomed.com/news/257.html

Roundup of #antibody #biotech deals in February 2026 👇 🤝 @Innovent_2011 announces strategic collaboration with @EliLillyandCo to develop new medicines globally in oncology and immunology, in potential $8.5B deal. en.innoventbio.com/InvestorsAndMe…

🎙️Listen to Episode 14 of Biointron’s Spotlight on Antibodies, a monthly podcast diving deep into the world of antibody innovation! This month in February: radioantibodies, antibody-cytokine fusion proteins, and conditionally active antibodies. 🔗 creators.spotify.com/pod/profile/bi…

On February 22, 2026, Biointron successfully completed its latest third-party #cybersecurity assessment conducted by @CyberVadis, achieving 923/1000 at the Mature security capability level, which is the highest level in the CyberVadis rating framework. biointron.com/company-news/b…

🧬 A recent study by @NRC_CNRC researchers examines how monoclonal antibody expression impacts CHO cell metabolism using online oxygen uptake rate (OUR) monitoring at the shake-flask scale. 🔗 doi.org/10.1016/j.jbio…